Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

The JAK inhibitor ruxolitinib reduces inflammation in an ILC3-independent model of innate immune colitis.

Overstreet AM, LaTorre DL, Abernathy-Close L, Murphy SF, Rhee L, Boger AM, Adlaka KR, Iverson AM, Bakke DS, Weber CR, Boone DL. The JAK inhibitor ruxolitinib reduces inflammation in an ILC3-independent model of innate immune colitis. Mucosal Immunol. 2018 09; 11(5):1454-1465.

View in: PubMed

collapse authors with profiles